Icure Pharmaceutical KRX:175250KOSDAQ
아이큐어 · Korean news coverage and regulatory filings, organized.
Articles, 24h1
Articles, 7 days5
DART filings, 7 days0
Articles tracked6since Sep 11
In Q2 2026, Icure Pharmaceutical reported revenue of ₩37.7bn, up 49.1% year on year, and operating profit of ₩2.4bn. Icure Pharmaceutical (아이큐어) appeared in 5 Korean news articles and 0 DART filings over the past seven days. Coverage peaked on Oct 29 with 4 articles.
Filing signals Turnaround Revenue +30% Insider buying Major holder adding Screener
Icure Pharmaceutical quarterly results consolidated, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q2 2026 | ₩37.7bn | +49.1% | ₩2.4bn margin 6.4% | ₩2.3bn |
| Q1 2026 | ₩32.2bn | +45.5% | ₩208m margin 0.6% | −₩669m |
| Q4 2025 derived | ₩10.9bn | -47.5% | −₩1.8bn margin −17.0% | −₩18.4bn |
| Q3 2025 | ₩25.1bn | +59.8% | −₩3.3bn margin −13.0% | −₩3.9bn |
| Q2 2025 | ₩25.3bn | +50.0% | −₩4.4bn margin −17.5% | −₩9.8bn |
| Q1 2025 | ₩22.1bn | +38.9% | −₩2.4bn margin −11.0% | −₩2.5bn |
| Q4 2024 derived | ₩20.7bn | +71.0% | −₩4.6bn margin −22.4% | −₩16.2bn |
| Q3 2024 | ₩15.7bn | +5.1% | −₩4.4bn margin −28.0% | ₩21.9bn |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.
Icure Pharmaceutical top stories 2 weeks, by number of outlets
- 1
- 2
Latest Icure Pharmaceutical news Korean headlines
-
아이큐어, '2026 홍콩 코스모팩 어워드' 스킨케어 포뮬라 부문 파이널리스트 선정
3 more on this story · 3 outlets
- 아이큐어 ‘일렉트래곤 젤 크림’, 홍콩 코스모팩 어워드 스킨케어 부문 파이널리스트 선정공감신문 · Oct 29 09:10
- 아이큐어, ‘2026 홍콩 코스모팩 어워드’ 스킨케어 포뮬라 부문 파이널리스트 선정이데일리 · Oct 29 09:41
- 아이큐어, ‘2026 홍콩 코스모팩 어워드’ 스킨케어 포뮬라 부문 파이널리스트 선정디지털타임스 · Oct 29 11:40